Napredna pretraga

Pregled bibliografske jedinice broj: 451460

Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats


Sever, Marko; Kliček, Robert; Radić, Božo; Brčić, Luka; Zoričić, Ivan; Drmić, Domagoj; Ivica, Mihovil; Barišić, Ivan; Ilić, Spomenko; Berkopić, Lidija et al.
Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats // Digestive diseases and sciences, 54 (2009), 10; 2070-2083 doi:10.1007/s10620-008-0598-y (međunarodna recenzija, članak, znanstveni)


Naslov
Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats

Autori
Sever, Marko ; Kliček, Robert ; Radić, Božo ; Brčić, Luka ; Zoričić, Ivan ; Drmić, Domagoj ; Ivica, Mihovil ; Barišić, Ivan ; Ilić, Spomenko ; Berkopić, Lidija ; Boban Blagaić, Alenka ; Ćorić, Marijana ; Kolenc, Danijela ; Vrčić, Hrvoje ; Anić, Tomislav ; Seiwerth, Sven ; Sikirić, Predrag

Izvornik
Digestive diseases and sciences (0163-2116) 54 (2009), 10; 2070-2083

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Gastric pentadecapeptide BPC 157; short bowel syndrome; rats

Sažetak
The gastric pentadecapeptide BPC 157, which was shown to be safe as an antiulcer peptide in trials for inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and fistula in rat. Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus. BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice). Postoperatively, features of increasingly exhausted presentation were: weight loss appearing immediately regardless of villus height, twofold increase in crypt depth and fourfold increase in muscle thickness within the first week, jejunal and ileal overdilation, and disturbed jejunum/ileum relation. In contrast, constant weight gain above preoperative values was observed immediately with BPC 157 therapy, both perorally and parenterally, and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days. Moreover, rats treated with pentadecapeptide BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength. In conclusion, pentadecapeptide BPC 157 could be helpful to cure short bowel syndrome.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekt / tema
108-0532264-0048 - Hepatocelularni tumori (Marijana Ćorić, )
108-1080321-0389 - Utjecaj pentadekapeptida BPC 157 na ženski urogenitalni sustav (Hrvoje Vrčić, )
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Predrag Sikirić, )
108-1083570-3636 - Učinak BPC 157 na induciranu bilijarnu opstrukciju (Tomislav Anić, )
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Sven Seiwerth, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati